

EUPATI Sustaining Partners 2024

Sustaining Partner eligibility criteria:

To be part of the SPA, a partner needs to have committed substantially to the continuation of EUPATI through contributing in-cash or in-kind to the EUPATI 2023 Programme and beyond. All currently existing National Platforms are also considered as Sustaining Partners.

List of EUPATI 2024 Sustaining Partners:

Industry	Patient Organisations	Academia/Non-Profit	National Platforms
Abbvie	Digestive Cancers Europe (DiCE)	Drug Information Association (DIA)	Austria
Almirall	European AIDS Treatment Group (EATG)	European Infrastructure for Translational Medicine (EATRIS)	Belgium
Amgen	European Federation of Allergy and Airways Diseases Patients' Associations (EFA)	European Clinical Research Infrastructure Network (ECRIN)	Czech Republic
AstraZeneca	European Liver Patients' Association (ELPA)	European Forum for Good Clinical Practice (EFGCP)	Cyprus
Bayer	European Patients' Forum (EPF)	European Organisation for Research and Treatment of Cancer (EORTC)	Denmark
Boehringer Ingelheim	Global Heart Hub (GHH)	FindMeCure Foundation	Finland
Bristol-Myers Squibb	Parkinson's Europe	ISPOR	France
Chiesi	The International Alliance of Dermatology Patient Organizations (GlobalSkin)	KU Leuven	Germany
CSL Behring	The Irish Platform for Patient Organisations, Science and Industry (IPPOSI)	Medical University of Vienna	Greece
Daiichi Sankyo		Sant Joan de Deu Research Institute	Ireland
Gilead		The Organisation for Professionals in Regulatory Affairs (TOPRA)	Italy
Greenphire		South East Technological University (SETU)	Japan
GlaxoSmithKline		University College Dublin	Luxembourg
Incyte		Vall d'Hebron University Hospital	Malta
Janssen			Netherlands
Lundbeck			Norway
Menarini			Poland
MSD			Portugal
Novartis			Scotland
Novo Nordisk			Slovakia
Novocure			Spain
Pfizer			Sweden
Roche			Switzerland
Servier			Turkey
Sobi			
Takeda			
UCB			
ViiV Healthcare			